101908-41-2

Usage

Uses

Used in Pharmaceutical Research:
N1-(2,4-DIMETHOXYPHENYL)-2-CHLOROACETAMIDE is used as a research compound for exploring its potential biological activities and medicinal properties. Its unique structure and functional groups may contribute to the development of new drugs, particularly in the areas of therapeutic intervention and disease treatment.
Used in Organic Chemistry:
In the field of organic chemistry, N1-(2,4-DIMETHOXYPHENYL)-2-CHLOROACETAMIDE serves as a key intermediate in the synthesis of novel organic compounds. Its reactivity and structural features allow for the creation of a variety of chemical entities, expanding the scope of organic synthesis and potentially leading to new materials and applications.
Used in Drug Development:
N1-(2,4-DIMETHOXYPHENYL)-2-CHLOROACETAMIDE is utilized as a starting material or building block in the development of new pharmaceutical agents. Its potential to interact with biological targets and exhibit therapeutic effects makes it a promising candidate for further exploration and optimization in drug discovery processes.

InChI:InChI=1/C10H12ClNO3/c1-14-7-3-4-8(9(5-7)15-2)12-10(13)6-11/h3-5H,6H2,1-2H3,(H,12,13)

Upstream product

• 79-04-9 chloroacetyl chloride 
• 2735-04-8 2,4-Dimethoxyaniline 
• 5307-06-2 N-(4-hydroxy-2-methoxyphenyl)acetamide 
• 61638-01-5 4-Amino-3-methoxyphenol 
• 106063-48-3 4-benzenesulfonic acid 
• 23042-75-3 N-(2,4-dimethoxyphenyl)acetamide 
• 150-19-6 O-methylresorcine 

Downstream Products

• 900882-02-2 C₂₆H₃₂N₄O₅S 
• 902556-85-8 C₂₅H₂₁N₃O₆S 
• 1431855-47-8 2-(2,4-dimethoxyphenylamino)-5-[3-(2,4-dimethoxyphenyl)-1-phenyl-1H-pyrazol-4-ylmethylene]thiazol-4-one 
• 1431855-46-7 5-[3-(2,4-dichlorophenyl)-1-phenyl-1H-pyrazol-4-ylmethylene]-2-(2,4-dimethoxyphenylamino)thiazol-4-one 
• 1431855-45-6 5-[3-(2-chlorophenyl)-1-phenyl-1H-pyrazol-4-ylmethylene]-2-(2,4-dimethoxyphenylamino)thiazol-4-one 
• 1431855-44-5 5-[3-(3-chlorophenyl)-1-phenyl-1H-pyrazol-4-ylmethylene]-2-(2,4-dimethoxyphenylamino)thiazol-4-one 
• 1431855-43-4 2-(2,4-dimethoxyphenylamino)-5-[3-(4-fluoro-phenyl)-1-phenyl-1H-pyrazol-4-ylmethylene]thiazol-4-one 
• 1431855-42-3 [3-(4-bromophenyl)-1-phenyl-1H-pyrazol-4-ylmethylene]-2-(2,4-dimethoxyphenylamino)thiazol-4-one 
• 1431855-41-2 [3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-ylmethylene]-2-(2,4-dimethoxyphenylamino)thiazol-4-one 
• 1020508-99-9 2-(2,4-dimethoxyphenylamino)-5-[3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-ylmethylene]thiazol-4-one 
• 1431855-40-1 2-(2,4-dimethoxyphenylamino)-5-(1-phenyl-3-p-tolyl-1H-pyrazol-4-ylmethylene)thiazol-4-one 
• 1431855-39-8 C₂₇H₂₂N₄O₃S 
• 1431855-48-9 2-(2,4-dimethoxyphenylamino)thiazol-4-one 
• 1232790-91-8 C₂₆H₂₁FN₄O₄ 

Relevant academic research and scientific papers

Synthesis and spectral characterisation of new amido-ether Schiff bases

Series of new compounds prepared by condensing the sodium salt of 4-[(4-methoxy-benzylidene)-amino]-phenol with chloroacetanilides carrying various substituents in different positions has been synthesised and characterised by UV-VIS, FTIR, MS, 1H and 13C NMR spectrometry. The effect of type and position of different substituents on thermal and on mesomorphic behaviour has been investigated by polarizing optical microscopy and differential scanning calorimetry studies. All compounds possess relatively high phase transition temperatures due to possibility of forming molecular associations and only the 2,4-substituted ones possess the liquid crystalline behaviour, namely the nematic phase.

Design and synthesis of novel xanthone-triazole derivatives as potential antidiabetic agents: α-Glucosidase inhibition and glucose uptake promotion

Inhibiting the decomposition of carbohydrates into glucose or promoting glucose conversion is considered to be an effective treatment for type 2 diabetes. Herein, a series of novel xanthone-triazole derivatives were designed, synthesized, and their α-glucosidase inhibitory activities and glucose uptake in HepG2 cells were investigated. Most of the compounds showed better inhibitory activities than the parental compound a (1,3-dihydroxyxanthone, IC50 = 160.8 μM)and 1-deoxynojirimycin (positive control, IC50 = 59.5 μM)towards α-glucosidase. Compound 5e was the most potent inhibitor, with IC50 value of 2.06 μM. The kinetics of enzyme inhibition showed that compounds 5e, 5g, 5h, 6c, 6d, 6g and 6h were noncompetitive inhibitors, and molecular docking results were consistent with the noncompetitive property that these compounds bind to allosteric sites away from the active site (Asp214, Glu276 and Asp349). On the other hand, the glucose uptake assays exhibited that compounds 5e, 6a, 6c and 7g displayed high activities in promoting the glucose uptake. The cytotoxicity assays showed that most compounds were low-toxic to human normal hepatocyte cell line (LO2). These novel xanthone triazole derivatives exhibited dual therapeutic effects of α-glucosidase inhibition and glucose uptake promotion, thus they could be use as antidiabetic agents for developing novel drugs against type 2 diabetes.

A convenient modified synthesis of 5-pyridinyl-1,3,4-thiadiazole-2-carboxamides

A general one-pot procedure is developed for the synthesis of 5-pyridinyl-1,3,4-thiadiazole-2-carboxamides by the reaction of pyridine carboxaldehydes with oxamic acid thiohydrazides. (Figure Presented).

GPR17 Receptor Modulators

Chemical compounds are provided which act on GPR17 receptors and are useful in the treatment or amelioration of chronic and/or acute neurodegenerative diseases, such as multiple sclerosis, inflammatory diseases, pathologies involving the immune system, cardiovascular diseases, and renal diseases.

Synthesis of new heterocyclic hybrids based on pyrazole and thiazolidinone scaffolds as potent inhibitors of tyrosinase

As a part of ongoing studies in developing new Tyrosinase inhibitors, a class of structurally novel 2-(2,4-dimethoxy phenylamino)-5 methylene-4- thiazolinone derivatives were synthesized by incorporating 2-(2,4-dimethoxy- phenylamino)-thiazol-4-one with various 1-(1-methyl-buta-1,3-dienyl)-3-phenyl- 1H-pyrazole-4-carbaldehyde. The results showed that some of the synthesized compounds exhibited significant inhibitory activities. Especially, 5-[3-(2-chloro-phenyl)-1-phenyl-1H-pyrazol-4-ylmethylene]-2-(2, 4-dimethoxy-phenylamino)-thiazol-4-one (5h) and 5-[3-(3-chloro-phenyl)-1-phenyl- 1H-pyrazol-4-ylmethylene]-2-(2,4-dimethoxy-phenylamino)-thiazol-4-one (5g) possessing 2-chloro-phenyl and 3-chloro-phenyl group exhibited the most potent tyrosinase inhibitory activity with an IC50 value of 34.12 and 52.62 μM, respectively. The inhibition mechanism analysis of 5h and 5g thiazolidinone derivatives demonstrated that the inhibitory effects of the compounds on tyrosinase were reversible and competitive. Preliminary structure-activity relationships (SAR) analysis suggested that further development of such compounds might be of interest, as it manifests simple reversible slow binding inhibition against monophenolase and diphenolase.

GPR17 RECEPTOR MODULATORS

The present invention relates to chemical compounds acting through GPR17 receptor for use in the treatment o f diseases, in particular for use in chronic and/or acute neurodegenerative diseases, preferably Multiple Sclerosis, inflammatory diseases, pathologies involving the immune system, cardiovascular diseases, renal diseases.

A novel synthesis of some 2-imino-4-thiazolidinone derivatives

(Chemical Equation Presented) An efficient and simple route is presented to the synthesis of some iminothiazolidinone derivatives. α-Chloro amide derivatives undergo coupling reaction with isothiocyanate in the presence of a mild base, followed by nucleophilic substitution of chlorine by the sulfur atom of isothiocyanate.

Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases

Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

Diaminopyrimidines as P2X3 and P2X2/3 antagonists

Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.